SEC charges ex-Sangamo exec with insider trading

The SEC charged Winson Tang, former VP of clinical research at Sangamo Therapeutics Inc. (NASDAQ:SGMO), and others with insider trading ahead of the biotech's 2014 licensing deal with Biogen Inc. (NASDAQ:BIIB).

In a filing, the SEC alleges Tang informed others in late 2013 about the agreement, leading to $1.5 million in illegal profits...